Medication info

Pregabalin Capsule 150mg (Pregabalin)

Prescription medicationHard capsuleOralExpired
Ingredient · strength
Pregabalin›150mg / 1 capsule
Manufacturer / importer
Daehan Newpharm Co., Ltd.
Appearance
A hard capsule with white powder inside, with white upper and lower parts.
Packaging
30 capsules/bottle, 100 capsules/bottle
Approval status
Expired

MFDS item code 201904607 · Approved 2019.07.08

This product's status changed to Expired on 2024.07.08. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of neuropathic pain, treatment of fibromyalgia, adjunctive treatment of partial-onset seizures
Who takes it
Adults · Children
Adult dose
This medicine is administered orally as pregabalin in 2 divided doses per day, regardless of food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Depending on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Depending on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Depending on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg to 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and, based on efficacy and tolerability, may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys in unchanged form. Since the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Administration regimen Starting dose (mg/day) Maximum dose (mg/day) ≥60: Starting dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30 -<60: Starting dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15 -<30: Starting dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15: Starting dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: Starting dose 25 mg, maximum dose 100 mg, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified under the administration regimen. b: Supplemental dose refers to an additional dose administered as a single dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (aged 65 years or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12~17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
Daehan Newpharm Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain, treatment of fibromyalgia, adjunctive treatment of partial-onset seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • epilepsy
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used to treat peripheral and central neuropathic pain in adults. It is also used as an adjunct in patients with epilepsy who experience partial seizures, particularly regardless of whether there are secondary general symptoms. Additionally, it is effectively used in the treatment of fibromyalgia.

How to take

Adult dose

This medicine is administered orally as pregabalin in 2 divided doses per day, regardless of food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Depending on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Depending on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Depending on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg to 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and, based on efficacy and tolerability, may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys in unchanged form. Since the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Administration regimen Starting dose (mg/day) Maximum dose (mg/day) ≥60: Starting dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30 -<60: Starting dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15 -<30: Starting dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15: Starting dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: Starting dose 25 mg, maximum dose 100 mg, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified under the administration regimen. b: Supplemental dose refers to an additional dose administered as a single dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (aged 65 years or older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12~17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, so mood changes or unusual behavior should be closely monitored during use. Do not take if allergic to pregabalin or any components of this drug. Diabetes patients may experience weight gain with this medication, necessitating possible adjustments in their blood glucose control medication dosage. Immediately stop taking this medication and consult with a healthcare professional if allergic reactions such as angioedema occur. Elderly patients should be cautious as dizziness or drowsiness may increase the risk of falls or injury while taking this medication. Blurry vision or changes in vision may occur while on this medication, and a doctor should be consulted if symptoms persist. Care should be taken when discontinuing this medication if it is being used in conjunction with other antiepileptic drugs. Stopping abruptly can lead to withdrawal symptoms such as insomnia, headache, and anxiety, so tapering off is necessary. This medication has the potential for abuse, so inform healthcare providers of mental health conditions and any history of drug use. Patients with reduced kidney function may require dosage adjustments, and kidney function may improve after discontinuation. Patients with heart failure should take caution while on this medication, and those with heart conditions should consult a healthcare provider. When taken with opioid analgesics, there is a risk of central nervous system depression, so special caution is warranted if used together. This medication can cause respiratory depression, so patients with respiratory diseases or kidney disorders may require dosage adjustments. Women of childbearing potential should be cautious during early pregnancy as there is a risk of fetal malformation; those planning to become pregnant should consult healthcare providers and use effective contraception. This medication can cause dizziness and drowsiness, so driving or operating dangerous machinery should be avoided until symptoms improve. Severe skin reactions, such as Stevens-Johnson syndrome, can rarely occur, so if abnormal skin symptoms arise, stop taking the medication immediately and inform a healthcare provider. This medication has low drug interaction potential, but taking it with alcohol or central nervous system depressants may increase the risk of drowsiness or respiratory depression. Pregnant or nursing women should consult healthcare providers before taking this medication and are advised to avoid it while breastfeeding. In cases of overdose, confusion, drowsiness, depression, seizures, etc., can occur, so immediate emergency treatment is necessary. This medication must be kept out of reach of children and should not be transferred to another container.

Side effects

  • suicidal thoughts
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • periorbital swelling
  • upper respiratory tract swelling
  • dizziness
  • drowsiness
Show 179 more
  • loss of consciousness
  • confusion
  • mental disorder
  • blurred vision
  • vision changes
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • depression
  • pain
  • seizures
  • sweating
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • decreased respiratory function
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensation reduction
  • ascites
  • swallowing difficulty
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweats
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urination disorders
  • urinary incontinence
  • reduced urinary output
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • nipple discharge
  • breast enlargement
  • peripheral edema
  • swelling
  • gait abnormality
  • falls
  • feeling intoxicated
  • altered sensation
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • increased serum creatinine
  • decreased white blood cell count
  • nasopharyngitis
  • neutropenia
  • increased appetite
  • loss of appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • hyperesthesia
  • anxiety
  • mood instability
  • emotional dejection
  • emotional elevation
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • impulsivity
  • apathy
  • ataxia
  • impaired motor coordination
  • balance disorders
  • amnesia
  • attention deficit
  • memory impairment
  • tremors
  • dysarthria
  • sensory abnormalities
  • sensory decrease
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • speech disorders
  • clonic spasms
  • reflex decrease
  • motor abnormalities
  • psychomotor agitation
  • positional dizziness
  • hypersensitivity
  • burning sensation
  • tremor during activity
  • syncope
  • confusion
  • hypokinesia
  • olfactory disturbances
  • loss of taste
  • writing difficulties
  • diplopia
  • auditory hypersensitivity
  • first degree AV block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • pharyngeal tension
  • nasal dryness
  • respiratory depression
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • drowsiness
  • confused state
  • agitation
  • restlessness
  • worsening of spasms
  • angioedema
  • allergic reaction
  • keratitis
  • pulmonary edema
  • shock
  • anaphylaxis-like symptoms
  • mucocutaneous syndrome
  • erythema multiforme

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to protect it from air and moisture. It is important to maintain the storage temperature between 15 and 30 degrees Celsius. This ensures the medication's effectiveness is safely preserved.

Appearance and packaging

Appearance

A hard capsule with white powder inside, with white upper and lower parts.

Package unit

30 capsules/bottle, 100 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.